ACELYRIN Inc (SLRN)

Form 15-12G - Securities registration termination [Section 12(g)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma...

Form 425 - Prospectuses and communications, business combinations

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE...

Form 425 - Prospectuses and communications, business combinations

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form DEFR14A - Revised definitive proxy soliciting materials

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio;...